Why Eagers Automotive is in the driver's seat
Why Eagers Automotive is in the driver's seat
About this video
Key points:
Healthcare names CSL and Cochlear viewed as recovering from oversold levels
Local SaaS leaders Xero and WiseTech seen as still expensive with higher AI-related risks
Eagers Automotive positioned to benefit from strong BYD EV momentum and sector divergence
Aaron Binsted from Lazard Asset Management states that healthcare and selected consumer names are emerging as attractive opportunities on the ASX. Over the past year, beaten-down healthcare heavyweights CSL (ASX:CSL) and Cochlear (ASX:COH) are described as recovering strongly from oversold levels. Binsted claims valuations had fallen to compelling multiples, with limited exposure to AI disruption compared with local SaaS names such as Xero (ASX:XRO) and WiseTech Global (ASX:WTC), which are viewed as still priced for very high growth.
Binsted highlights Eagers Automotive (ASX:APE) as a key consumer-exposed opportunity. He points to recent trading updates suggesting solid growth while listed peers Peter Warren Automotive (ASX:PWR) and Autosports Group (ASX:ASG) flag much weaker conditions. In his view, Eagers’ lower cost base and leverage to surging BYD electric vehicle volumes in Australia support potential earnings upgrades, particularly as BYD’s market share appears to be rising sharply.
Treasury Wine Estates (ASX:TWE) is also flagged as interesting following a difficult two-year period. Binsted notes new CEO Sam Fischer’s FY26 earnings guidance as slightly above market expectations and interprets it as signalling possible earnings stability. With the company trading below book value and deliberately under-earning while clearing inventory and rationalising brands towards premium labels such as Penfolds, Binsted considers this a potential turning point.